New cystic fibrosis drug regimen considered a breakthrough treatment

A three-drug combination sold under the brand name A three-drug
combination sold under the brand name Trikafta Trikafta was
approved by the was approved by the Food and Drug Administration
Food and Drug Administration in October for people age 12 and older
with cystic fibrosis. in October for people age 12 and older with
cystic fibrosis. Christopher Fortner, MD, PhD Christopher Fortner,
MD, PhD, medical director of the cystic fibrosis program at
Upstate, describes how this treatment works, its side effects and
what it may mean for many of the people with this disease. Cystic
fibrosis causes persistent lung infections and limits the ability
to breathe over time, among other problems., medical director of
the cystic fibrosis program at Upstate, describes how this
treatment works, its side effects and what it may mean for many of
the people with this disease. Cystic fibrosis causes persistent
lung infections and limits the ability to breathe over time, among
other problems.